Feature | June 24, 2015

Early-Stage Breast Cancer Imaging Rates for Metastatic Cancer High Despite Guidelines

Canadian study finds 86 percent of women undergo pre- or postoperative imaging for peace of mind, against recommendations

early-stage breast cancer, metastatic, guidelines, CMAJ, University of Ottawa

June 24, 2015 - Most women with early-stage breast cancer will undergo imaging to determine if the cancer has metastasized, despite international guidelines that recommend against testing, found a study in Canadian Medical Association Journal (CMAJ).

Guidelines from the American Society of Clinical Oncology, Cancer Care Ontario and the National Comprehensive Cancer Network recommend against imaging for metastatic cancer in asymptomatic women with stage I or II breast cancer; this is because the likelihood of metastases is low, at 0.2 percent and 1.2 percent, respectively, and the chance of false-positive findings are high. Unnecessary investigation can result in harm because false-positive results can lead to more invasive tests, treatment delays and increased anxiety.

"Despite guidelines against imaging to detect radiologically-evident distant metastases, our results show that this practice is very common among patients with early-stage breast cancer in Ontario," wrote Mark Clemons, M.D., an oncologist at The Ottawa Hospital and the University of Ottawa, Ottawa, Ontario, with coauthors.

A study of 26,547 women in Ontario diagnosed with stage I or stage II breast cancer between 2007 and 2012 found that 86 percent (22,811) underwent at least one imaging test to detect whether the cancer had metastasized. Imaging was performed in about 80 percent of women with stage I breast cancer and about 93 percent (11,882) in those with stage II. The average number of tests performed per patient was 3.7 in the pre- and postoperative periods. Surgeons and oncologists ordered the most tests, with surgeons ordering 74 percent of preoperative tests and oncologists ordering about 41 percent of postoperative tests.

The researchers found that the use of advanced imaging, such as computed tomography, magnetic resonance imaging and positron emission tomography, to investigate possible metastases, has increased and now comprises 41 percent of all initial tests.

There was also variability in use of imaging between geographic regions in the province and between community hospitals and academic institutions.

"If guideline recommendations are to be implemented in practice, additional knowledge translation strategies are needed, as dissemination of clinical practice guidelines alone is not an effective method of changing physician practice behaviors. ... These strategies will also require patient engagement," concluded the authors

In a related commentary, Daniel Rayson, M.D., and Geoff Porter, M.D., of Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, Nova Scotia, wrote, "Both teams [surgical and oncological] may order tests to reassure and support the anxious, newly diagnosed patient and her loved ones - clearly laudable goals. Patients are often blindsided by a cancer diagnosis and rely on their medical team to be as certain as possible that their disease can be cured and they are not dying."

However, testing has a cascading effect, because recommendations for more confirmatory tests, increased wait times for results and possible treatment can heighten patient and family anxiety as well as increase costs and use of healthcare resources.

"It is the responsibility of physicians to be knowledge brokers between the evidence-based guidance and their patients. To do so effectively takes time, energy and good interdisciplinary communication. ... For most patients with newly diagnosed stage I and II breast cancer, reflexively ordering staging investigations does not help relieve stress, nor does it detect disease," stated the commentary authors.

For more information: www.cmaj.ca

Related Content

Volpara Solutions to Showcase VolparaEnterprise Live! at RSNA
News | Mammography | October 16, 2017
Volpara Solutions will introduce VolparaEnterprise Live!, a mammography quality control tool, at the 2016 Radiological...
TMIST Mammography Study Opens Enrollment
News | Mammography | October 16, 2017
The Tomosynthesis Mammographic Imaging Screening Trial (TMIST), the first randomized trial to compare two types of...
National Breast Center Founder Names Top Three Innovations in Breast Cancer Treatment
News | Women's Health | October 11, 2017
In 2017, invasive breast cancer will be diagnosed in about 252,710 women and 2,470 men in the U.S. and remains the...
News | Brachytherapy Systems | October 05, 2017
External researchers presented new clinical data supporting the use of iCAD’s Xoft Axxent Electronic Brachytherapy (eBx...
Joint Venture Partnership Opening 16 New Breast Screening Sites in Texas
News | Breast Imaging | October 04, 2017
HCA Healthcare Gulf Coast Division and Solis Mammography have entered into a joint venture agreement to make breast...
International Trial Confirms Safety, Effectiveness of High-Dose Brachytherapy Plus Pelvic Radiation for Cervical Cancer
News | Brachytherapy Systems, Women's Healthcare | October 04, 2017
Findings from a new multicenter, international clinical trial confirm the effectiveness of high-dose brachytherapy or...
Kubtec Announces Expansion of 3-D Tomosynthesis Technology
News | Digital Radiography (DR) | October 04, 2017
October 4, 2017 — Kubtec announced at the annual conference of the American Association of Pathology Assistants (AAPA
The Siemens Acuson

The Siemens Acuson

Feature | Breast Imaging | October 04, 2017 | By Melinda Taschetta-Millane
According to a new Market Study Report,1 the automated breast ultrasound system (ABUS) market will see a 21 percent...
Why guidelines aren't just for patients

Image courtesy of Eizo

Feature | Women's Health | October 04, 2017 | By Stamatia Destounis, M.D., FACR
Over the years, significant progress has been made educating women, men and families about breast cancer — the pink...
Hologic’s new Brevera breast biopsy system allows real-time tissue sample collection and verification on one system

Hologic’s new Brevera breast biopsy system allows real-time tissue sample collection and verification on one system.

Feature | Breast Imaging | October 03, 2017 | By Jeff Zagoudis
When it comes to breast imaging, mammography has long been the gold standard among breast cancer detection technologies...
Overlay Init